USA flag logo/image

An Official Website of the United States Government

TARGET TO SPECIFIC LYMPHOID CELLS. PHASE I. MACROPHAGE TARGETING.

Award Information

Agency:
National Science Foundation
Branch:
N/A
Award ID:
763
Program Year/Program:
1983 / SBIR
Agency Tracking Number:
763
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Vestar, Inc.
650 Cliffside Drive San Dimas, CA 91773
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1983
Title: TARGET TO SPECIFIC LYMPHOID CELLS. PHASE I. MACROPHAGE TARGETING.
Agency: NSF
Contract: N/A
Award Amount: $35,000.00
 

Abstract:

A THREE PHASE PROJECT IS PROPOSED TO COMMERCIALIZE FORMULATIONS OF PHOSPHOLIPID VESICLES CAPABLE OF DELIVERING IMMUNOGENIC SUBSTANCES TO SPECIFIC LYMPHOID CELLS. PHASE I IS A PROOF OF CONCEPT STUDY DESIGNED TO DEMONSTRATE THAT A VESICLE FORMULATION KNOWN TO AGGRESSIVELY TARGET TO MACROPHAGE IN VITRO CAN EVOKE STRONG MACROPHAGE MEDIATED IMMUNE RESPONSES TO OTHERWISE WEAK OR NONIMMUNOGENIC HAPTEN CONJUGATES IN VIVO. PHASE I EXPERIMENTS SPECIFICALLY ADDRESS THE MACROPHAGE MEDIATED B-CELL RESPONSE AND ARE DESIGNED TO DETERMINE THE SIGNIFICANCE OF THE SIZE OF THE HAPTEN CARRIER WHEN TARGETED WITH VESICLES. PHASE I SHOULD SUGGEST ANSWERS TO THE FOLLOWING QUESTIONS: 1) IS AN ENDOCYTOSED VESICLE PROCESSED AS AN IMMUNOGEN BEFORE OR AFTER LYSIS BY MACROPHAGE? 2) ARE LYSOZOME LABILE CARRIERS PROCESSED AS ANTIGENS OR DEGRADED WHEN ENDOCYTOSED WITHIN TARGETED VESICLES? 3) ARE HAPTEN-CONJUGATES, TARGETED TO MACROPHAGE BY VESICLE ENCAPSULATION, IMMUNOGENIC AT LOWER DOSAGES THAN CONVENTIONALLY INTRODUCED HAPTEN-CONJUGATES? SUCCESSFUL COMPLETION OF PHASE I WILL DEMONSTRATE THAT IMMUNE RESPONSE CAN BE ALTERED BY PRESENTING CHEMICAL SUBSTANCES TO SPECIFIC CELLS IN A MICROENCAPSULATED FORMULATION. PHASE II WILL EXTEND THIS PRELIMINARY INVES- TIGATION OF DELIVERING HAPTEN-CONJUGATE FORMULATIONS TO MACROPHAGE TO INCORPORATE HELPER T-CELL PARTICIPATION IN THEINITIAL ANTICIPATED T-CELL INDEPENDENT RESPONSE. THE PRODUCTION OF IMMUNE RESPONSES TO WEAKLY IMMUNOGENIC OR NON-IMMUNOGENIC MATERIALS HAS SIGNIFICANT SCIENTIFIC AND MEDICALAPPLICATIONS.

Principal Investigator:

Joseph a. uliana ph.d.
PRINCIPAL INVESTIGATOR

Business Contact:

Small Business Information at Submission:

Vestar Research Inc.
939 East Walnut St. Pasadena, CA 91106

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No